Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of cladribine + CAG in newly diagnosed elderly acute myeloid leukemia
ChiCTR-OIC-15007583Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine, filgrastim, cytarabine and aclarubicin in acute myeloid leukemia (AML), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Complete response rate after induction chemotherapy. Planned start Jan 2016; status: not yet recruiting.
02
Drugs
cladribinefilgrastimcytarabineaclarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OIC-15007583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-15007583.